September 9th 2025
Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) and works by targeting the source of inflammation.
September 2nd 2025
Dry eye specialists weigh in on what role dry eye plays in their practices.
August 8th 2025
New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.
August 7th 2025
TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.
August 4th 2025
Due to ubiquity, optometrists tend to undertreat patients with dry eye.
FDA accepts NDA of NOV03 for DED associated with MGD
Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.
Corticosteroids for DED flares: safe, effective
FDA-approved steroid offers short-term relief for ocular surface inflammation.
Dry eye and flares: make education a priority
Ensure successful symptoms management with your patients.
Alcon to acquire Aerie Pharma, expanding ophthalmic pharma portfolio
Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.
Optometry Divas: Empowering optometric thought leaders
Optometry Times' editor Kassi Jackson speaks with Lauretta Justin, OD, founder of Optometry Divas, and Lisa Hornick, OD, recipient of Optometry Divas' Thought Leader of the Year 2022 award.
Aerie doses first patient in COMET-3 study for DED treatment
COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.
How dry eye awareness social media campaigns benefit both patients and practices
One OD shares his experience launching a successful social media campaign for Dry Eye Awareness month—and offers 3 tips for crafting a message to capture an audience's attention.
New CL drug delivery system for DED
Contact lenses soaked in melatonin analogs may be able to address aqueous tear deficient dry eye disease, researchers say.
Dr. Sicks' #1 tip for managing dry eye
Lindsay A. Sicks, OD, FAAO, shares her number 1 tip for managing dry eye.
SCHs: mild trauma or something more sinister?
Case gives new perspective on subconjunctival hemorrhages
AOA launches Screen Time Alliance, partnership for Eye Deserve More campaign
The first-of-its-kind alliance and latest phase of AOA's national public awareness campaign focuses on the effects of extended time on digital devices and its impact on eye health.
Dr. Michaud's #1 tip for managing dry eye
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, shares his number 1 tip for managing dry eye.
Preparation is key to fighting dry eye while traveling
Best practices to help patients enjoy their trip to the fullest.
Dr. Coyne's #1 tip for managing dry eye
Alissa M. Coyne, OD, FAAO, FASOS, gives her number 1 tip for managing dry eye.
Bausch + Lomb, Novaliq submit NDA for NOV03 to treat DED associated with MGD
Drug submission of the first water-free therapy took place at the end of June, according to the companies.
Novartis acquires Kedalion Therapeutics and its ocular delivery platform
The company intends to develop the AcuStream technology for potential use with its current and future front-of-eye therapies, which may include lifitegrast ophthalmic solution for the treatment of dry eye disease.
Dr. Casella's #1 tip for managing dry eye
Optometry Times'® Chief Optometric Editor Ben Casella, OD, FAAO, gives his number 1 tip for managing DED.
Study: Varenicline nasal spray shows positive safety and tolerability profile
Leslie O'Dell, OD, FAAO, shares new research around OC-01 (varenicline solution) nasal spray, presented during the AOA 2022 meeting.
Therapy options based on DED severity
A plethora of treatments are available when patients, particularly contact lens wearers, are assessed at disease onset.
Optometry Times' Dr. Casella reflects on his time so far at AOA 2022
Optometry Times'® Chief Optometric Editor Ben Casella, OD, FAAO, shares some reflections on his time so far at the 2022 AOA Optometry's Meeting in Chicago.
Q&A: Streamlining the dry eye patient process in practice
Maria Sampalis, OD, discusses streamlining the dry eye process in her practice for optimum efficiency.
Dr. Anshel offers guidelines on eyestrain management in new book
Jeffrey Anshel, OD, FAAO, offers a sneak peek of his latest book titled "What you must know about eyestrain."
Q&A: Setting up a dry eye patient schedule
Maria Sampalis, OD, shares what a typical schedule for dry eye patients looks like on a daily and weekly basis at her practice.
Q&A: How to make your dry eye practice unique
Maria Sampalis, OD, shares how her practices is able to set itself apart from others within the dry eye field.
Wrong eye medicine
See this week's cartoon!
Aerie doses first patient in phase 3 DED treatment study
The COMET-2 study is the first of three studies in the AR-15512 phase 3 registration program, with topline results expected by the second half of 2023.
Q&A: Pandemic's effect on dry eye patient numbers
Maria Sampalis, OD, continues her dry eye discussion what factors she considers when diagnosing and treating patients.
Compounded medications in ophthalmic patient care
This far-less-understood option can fill multiple needs for a practice.
Q&A: Factors to consider when treating dry eye patients
Maria Sampalis, OD, continues her dry eye discussion by sharing what factors she considers when diagnosing and treating patients.
Shared care of the ocular surface before and after cataract surgery
Practices must efficiently integrate optometry and ophthalmology, delegating appropriate care to the proper specialist, in order to ensure patients’ total eye care needs are best met.